EP
Eversept Partners Portfolio holdings
AUM
$992M
This Quarter Return
+50.75%
1 Year Return
+2.54%
3 Year Return
+103.47%
5 Year Return
+181.01%
10 Year Return
–
AUM
$492M
AUM Growth
+$492M
(+54%)
Cap. Flow
+$111M
Cap. Flow
% of AUM
22.65%
Top 10 Holdings %
Top 10 Hldgs %
53.05%
Holding
79
New
22
Increased
21
Reduced
20
Closed
8
Top Buys
| 1 |
CCXI
ChemoCentryx, Inc.
CCXI
|
$20.3M |
| 2 |
BioCryst Pharmaceuticals
BCRX
|
$14.7M |
| 3 |
Pennant Group
PNTG
|
$12.3M |
| 4 |
Sanofi
SNY
|
$10.1M |
| 5 |
MDCO
Medicines Co
MDCO
|
$9.71M |
Top Sells
| 1 |
AMRN
Amarin Corp
AMRN
|
$8.88M |
| 2 |
ZGNX
Zogenix, Inc.
ZGNX
|
$7.72M |
| 3 |
Alnylam Pharmaceuticals
ALNY
|
$7.4M |
| 4 |
DexCom
DXCM
|
$7.11M |
| 5 |
ABMD
Abiomed Inc
ABMD
|
$5.33M |
Sector Composition
| 1 | Healthcare | 86.78% |
| 2 | Real Estate | 1.94% |
| 3 | Communication Services | 1.48% |
| 4 | Industrials | 1.1% |
| 5 | Financials | 0.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
GSK
GSK
$79.9B
| $48.6M | 8.58% | 1,023,085 +40,000 | +4% | +$1.9M |
|
2
The Ensign Group
ENSG
$9.91B
| $30.7M | 5.42% | 676,058 +89,384 | +15% | +$4.06M |
|
3
Danaher
DHR
$147B
| $30.3M | 5.35% | 197,107 +18,403 | +10% | +$2.83M |
|
4
Ascendis Pharma
ASND
$11.8B
| $28.2M | 4.98% | 202,894 -33,498 | -14% | -$4.66M |
|
|
ZGNX
5
DELISTED
Zogenix, Inc.
ZGNX
| $25.8M | 4.56% | 495,645 -148,173 | -23% | -$7.72M |
|
|
6
Sanofi
SNY
$121B
| $22.2M | 3.92% | 441,661 +201,661 | +84% | +$10.1M |
|
|
CCXI
7
DELISTED
ChemoCentryx, Inc.
CCXI
| $20.3M | 3.58% | +513,189 | New | +$20.3M |
|
|
AMRN
8
Amarin Corp
AMRN
$311M
| $19.6M | 3.47% | 915,590 -414,105 | -31% | -$8.88M |
|
|
BOLD
9
DELISTED
Audentes Therapeutics, Inc
BOLD
| $18.3M | 3.23% | 305,726 +52,000 | +20% | +$3.11M |
|
|
10
BioCryst Pharmaceuticals
BCRX
$1.74B
| $16.9M | 2.99% | 4,904,460 +4,250,000 | +649% | +$14.7M |
|
11
Vertex Pharmaceuticals
VRTX
$100B
| $16M | 2.82% | 73,009 +22,100 | +43% | +$4.84M |
|
12
Envista
NVST
$3.52B
| $15M | 2.65% | 506,678 +188,678 | +59% | +$5.59M |
|
|
13
Pennant Group
PNTG
$830M
| $12.3M | 2.17% | +371,193 | New | +$12.3M |
|
|
MDCO
14
DELISTED
Medicines Co
MDCO
| $9.71M | 1.72% | +114,358 | New | +$9.71M |
|
15
Sarepta Therapeutics
SRPT
$1.78B
| $9.68M | 1.71% | +75,000 | New | +$9.68M |
|
16
Apellis Pharmaceuticals
APLS
$3.48B
| $9.5M | 1.68% | 310,409 +230,900 | +290% | +$7.07M |
|
17
TG Therapeutics
TGTX
$4.65B
| $8.62M | 1.52% | 776,323 +2,822 | +0.4% | +$31.3K |
|
|
DCPH
18
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $8.01M | 1.42% | 128,748 +106,748 | +485% | +$6.64M |
|
|
MODN
19
DELISTED
MODEL N, INC.
MODN
| $7.28M | 1.29% | 207,615 +86,920 | +72% | +$3.05M |
|
20
Fate Therapeutics
FATE
$120M
| $7.06M | 1.25% | 360,656 +220,000 | +156% | +$4.31M |
|
21
AstraZeneca
AZN
$248B
| $7.01M | 1.24% | +140,562 | New | +$7.01M |
|
|
BLUE
22
DELISTED
bluebird bio
BLUE
| $6.44M | 1.14% | +73,400 | New | +$6.44M |
|
|
RDUS
23
DELISTED
Radius Health, Inc.
RDUS
| $6.43M | 1.14% | 318,811 -25,887 | -8% | -$522K |
|
24
argenx
ARGX
$43.6B
| $5.97M | 1.05% | 37,204 +1,200 | +3% | +$193K |
|
25
Illumina
ILMN
$15.8B
| $5.89M | 1.04% | 17,750 -9,000 | -34% | -$2.99M |
|